

**Supplementary Table.** Sensitivity analysis of modified intention-to-treat and per-protocol cohorts\*

<b>Outcome</b>	<b>mITT cohort (n=102)</b>	<b>Per-protocol cohort (n=95)</b>	<b>Effect estimate HR (95% CI)</b>
3-year OS rate (%)	74%	76%	1.08 (0.66-1.77)
3-year DFS rate (%)	66%	68%	1.12 (0.71-1.89)
3-year MFS rate (%)	77%	79%	1.05 (0.62-1.81)

mITT: modified intention-to-treat, HR: Hazard ratio, CI: Confidence interval, OS: Overall survival, DFS: Disease-free survival, MFS: Metastasis-free survival

\*Sensitivity analyses including self-expandable metallic stent failures and urgent surgeries did not materially alter survival estimates compared with the per-protocol cohort.